INVESTORS
Engrail is a clinical-stage pharmaceutical company with a rich pipeline of precision-targeted neuroscience programs designed to improve the lives of patients with neuropsychiatric and neurodevelopmental diseases. We apply precision chemistry and pharmacology to develop transformative medicines for patients who have been underserved by existing treatments.
Our lead program, ENX-102, is a next-generation GABAA positive allosteric modulator (PAM) in Phase 2 clinical development for the treatment of generalized anxiety disorder. Additional clinical and preclinical programs are intended to address significant unmet medical needs for the treatment of depression and anhedonia, posttraumatic stress disorder, and other anxiety-, mood-, and stress-related disorders. We are also developing a potentially life-saving and quality-of-life improving approach to the treatment of Menkes disease, an ultra-rare and fatal neurodevelopmental disease of deficient copper transport.
We invite you to learn more about our exciting and diverse neuroscience pipeline, experienced leadership team, and unique scientific approach.
MEDIA
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) — Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced initiation of a Phase 1 single ascending dose clinical study for ENX-104 in healthy volunteers. ENX-104 is a potent and selective dopamine D2/D3 receptor antagonist designed to enhance dopamine neurotransmission by preferential autoreceptor inhibition at low doses. The lead indication for ENX-104 is the treatment of major depressive disorder (MDD) characterized by anhedonia (aMDD). Anhedonia is the inability to experience pleasure in normally pleasurable activities and is a core symptom of MDD that is largely unresponsive to currently approved antidepressants.
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
SAN DIEGO, August 8, 2024 — Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the appointment of Paul Cayer as chief financial officer, and Saira Ramasastry to the company’s board of directors. Ms. Ramasastry will assume the position of chair of the audit committee. The company also announced the receipt of a $10 million investment from Foresite Capital in an extension of the Series B financing announced in March 2024, bringing the total raised in the Series B round to $167 million.
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
SAN DIEGO – March 19, 2024 – Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences. Since its inception in 2019, the Company has raised over $220 million.
Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD). ENX-102 is an investigational, highly selective GABA-A α2,3,5 positive allosteric modulator (PAM) and antagonist at α1-containing GABA-A channels. ENX-102 represents a first-in-class approach to the treatment of GAD.
Engrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy
SAN DIEGO – June 7, 2022 – Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, has announced positive results from a phase 1b clinical trial of ENX-101, a subtype-selective GABA-A positive allosteric modulator (PAM). The phase 1b clinical trial data were presented on June 6, 2022, at the 2022 Epilepsy Pipeline Conference in Santa Clara, California.
Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement for Elesclomol in Disorders of Mitochondrial Copper Metabolism
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS), today announced that they have entered into a license agreement which grants Engrail worldwide exclusive rights to intellectual property around the use of elesclomol for disorders of mitochondrial copper metabolism.